GenSight Biologics begins treating ND4-LHON patients under France's AAC compassionate access program. Analyse what REVISE and AAC mean for the regulatory pathway.
YUVEZZI becomes the first FDA-approved dual-agent eye drop for presbyopia. Find out what this means for Tenpoint Therapeutics and the future of vision care.
Novaliq’s NOV05 enters Phase 2 trials for anterior uveitis. Can it deliver steroid-free, topical relief for inner-eye inflammation? Find out what’s next.
Mu Medical unites Nanodropper, Bedo, and Viseon into a precision eyecare platform. Find out what this could mean for the future of AI-led ophthalmology.
GenEditBio Limited, a Hong Kong–headquartered clinical-stage biotechnology firm focused on in vivo genome-editing therapies, announced that the United States Food and Drug Administration has cleared its Investigational New Drug application for GEB‑101, a CRISPR-based candidate for TGFBI corneal dystrophy. This regulatory milestone authorizes the launch of the Phase 1/2 CLARITY trial in the United States,